Use of interleukin-22 in the treatment of fatty liver disease

Abstract

The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.

What is claimed is: 
     
         1 . A method for treatment of fatty liver, wherein said method comprises administering to a subject in need of treatment a composition, said composition comprises a pharmaceutically effective amount of IL-22. 
     
     
         2 . The method according to  claim 1 , wherein said composition reduces steatosis. 
     
     
         3 . The method according to  claim 1 , wherein said composition decreases serum triglyceride level. 
     
     
         4 . The method according to  claim 1 , wherein said composition decreases transaminase level. 
     
     
         5 . The method according to  claim 1 , wherein said IL-22 is human IL-22. 
     
     
         6 . The method according to  claim 1 , wherein said IL-22 is encoded by the polynucleotide of SEQ ID NO. 1. 
     
     
         7 . The method according to  claim 1 , wherein said fatty liver disease is alcoholic fatty liver disease or non-alcoholic fatty liver disease. 
     
     
         8 . The method according to  claim 1 , wherein said composition reduces body weight. 
     
     
         9 . The method according to  claim 1 , wherein said composition reduces liver weight. 
     
     
         10 . The method according to  claim 1 , wherein the pharmaceutically effective amount of IL-22 is 10 μg/kg/d-300 μg/kg/d in a mammal. 
     
     
         11 . The method according to  claim 1 , wherein the pharmaceutically effective amount of IL-22 is 10 μg/kg/d-100 μg/kg/d in a mammal.